Contrasting AC Immune (NASDAQ:ACIU) & Takeda Pharmaceutical (NASDAQ:TKPYY)
AC Immune (NASDAQ:ACIU) and Takeda Pharmaceutical (OTCMKTS:TKPYY) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, valuation, earnings, analyst recommendations, profitability and risk.
Earnings & Valuation
This table compares AC Immune and Takeda Pharmaceutical’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|AC Immune||$7.36 million||53.24||-$52.09 million||($0.82)||-7.07|
|Takeda Pharmaceutical||$15.99 billion||0.00||$1.68 billion||N/A||N/A|
Risk & Volatility
AC Immune has a beta of 0.74, meaning that its share price is 26% less volatile than the S&P 500. Comparatively, Takeda Pharmaceutical has a beta of 0.42, meaning that its share price is 58% less volatile than the S&P 500.
This is a summary of recent ratings for AC Immune and Takeda Pharmaceutical, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
AC Immune currently has a consensus target price of $11.00, indicating a potential upside of 89.66%.
Institutional & Insider Ownership
28.3% of AC Immune shares are held by institutional investors. Comparatively, 0.2% of Takeda Pharmaceutical shares are held by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
This table compares AC Immune and Takeda Pharmaceutical’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
AC Immune beats Takeda Pharmaceutical on 6 of the 9 factors compared between the two stocks.
About AC Immune
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company's lead product candidate is crenezumab, a humanized, monoclonal, and conformation-specific anti-Abeta antibody, which is in Phase III clinical studies for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase I/IIa clinical study for AD; and ACI-35, an anti-Tau vaccine candidate against phosphorylated pathological tau and is in Phase Ib clinical testing in patients with mild to moderate AD, as well as RO7105705, an anti-Tau monoclonal antibody candidate, which is in Phase II clinical study for AD patients. In addition, the company has discovery and pre-clinical stage molecules targeting neurodegenerative diseases, as well as diagnostics targeting Tau, alpha-synuclein, and TDP-43 aggregates. It has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Piramal Imaging; Eli Lilly and Company; Essex Bio-Technology Limited; and WuXi Biologics, as well as Nestlé Institute of Health Sciences. AC Immune SA was founded in 2003 and is headquartered in Lausanne, Switzerland.
About Takeda Pharmaceutical
Takeda Pharmaceutical Company Limited engages in the research and development, manufacture, marketing, and sale of pharmaceutical products worldwide. The company operates in three segments: Prescription Drug, Consumer Healthcare, and Other. It offers prescription, OTC, and quasi-drugs; and reagents in various therapeutic areas, including oncology, gastroenterology, central nervous system (CNS), vaccines, and others. The company is also involved in clinical diagnostics, chemical products, and other businesses. Takeda Pharmaceutical Company Limited has a research collaboration with Shattuck Labs, Inc. to develop checkpoint fusion proteins that have the potential to become immunotherapies; and a collaboration alliance with Stanford University. It also has collaboration agreement with Samsung Bioepis Co., Ltd. to co-develop various biologic therapies; AstraZeneca PLC to develop and commercialize MEDI1341, an alpha synuclein antibody for the treatment of Parkinson's disease; Noile-Immune Biotech Inc. for the research and development of cancer immunotherapy; HitGen Ltd for the DNA-encoded library based drug discovery research; Montreal Neurological Institute to discover and develop treatments for amyotrophic lateral sclerosis; Denali Therapeutics to develop and commercialize therapeutic product candidates for neurodegenerative diseases; Fujifilm to develop regenerative medicine product for heart patients; Wave Life Sciences Ltd. to discover, develop, and commercialize nucleic acid therapies for disorders of CNS, as well as drugs for neglected diseases initiative; and Molecular Templates to develop CD38-targeted engineered toxin bodies. In addition, the company has a licensing agreement with Fimecs, Inc. for the development of novel immuno-oncology therapies; and a clinical collaboration with Nektar Therapeutics to evaluate the combination of NKTR-214 and TAK-659. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Osaka, Japan.
Receive News & Ratings for AC Immune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune and related companies with MarketBeat.com's FREE daily email newsletter.